scholarly journals Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies

2020 ◽  
Vol 34 (8) ◽  
pp. 829-838
Author(s):  
Nicole Meade ◽  
Lily Shi ◽  
Stine R Meehan ◽  
Catherine Weiss ◽  
Zahinoor Ismail
Keyword(s):  
Least Squares ◽  
Social Performance ◽  
Mean Difference ◽  
Syndrome Scale ◽  
Scale Total Score ◽  
Short And Long Term ◽  
Negative Syndrome ◽  
Performance Scale ◽  
Long Term Studies

Background: The treatment of patients with severe schizophrenia symptoms can be complicated and expensive. Aims: The purpose of this study was to evaluate the short- and long-term effects of brexpiprazole in patients with schizophrenia presenting with severe symptoms. Methods: Data were pooled from three six-week, randomized, double-blind, placebo-controlled studies and two 52-week, open-label extension studies. In the short-term studies, 1405 patients received placebo or brexpiprazole 2–4 mg/day; 412 brexpiprazole-treated patients rolled over into the long-term studies and received brexpiprazole 1–4 mg/day. More severe symptoms were defined as a Positive and Negative Syndrome Scale Total score >95 (median score at baseline). Outcomes included change in Positive and Negative Syndrome Scale Total and Personal and Social Performance scale scores. Results: Brexpiprazole improved Positive and Negative Syndrome Scale Total score over 6 weeks among more severely ill patients, with a least squares mean difference versus placebo of −6.76 (95% confidence limits: −9.80, −3.72; p<0.0001; Cohen’s d: 0.43). Brexpiprazole also improved Personal and Social Performance scale score over 6 weeks in more severely ill patients (least squares mean difference: 4.38; limits: 2.14, 6.62; p=0.0001; Cohen’s d: 0.38). Improvement of functioning was greatest in the ‘Self-care’ domain, followed by ‘Personal and social relationships’. Among less severely ill patients, brexpiprazole was superior to placebo on Positive and Negative Syndrome Scale Total and Personal and Social Performance scale at Week 6. Improvements were maintained over 58 weeks. No new safety or tolerability concerns were observed. Conclusions: Brexpiprazole is an efficacious and well-tolerated treatment for schizophrenia in patients with more severe, and less severe, symptoms.

scholarly journals Tratamento em regime compulsivo ambulatório: estudo de follow-up após um ano em Portugal

2017 ◽  
pp. 21-9
Author(s):  
Sofia Brissos ◽  
Sofia Brissos ◽  
Gonçalo Sobreira ◽  
João Miguel Oliveira ◽  
Zita Gameiro ◽  
...  
Keyword(s):  
Mental Disorder ◽  
Word Association ◽  
Social Performance ◽  
Digit Span ◽  
Association Test ◽  
Word Association Test ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Performance Scale

Enquadramento: Não existem evidências suficientes relativamente ao impacto do tratamento em regime compulsivo ambulatório (TCA). Objetivos: Avaliámos o impacto do TCA ao longo de um ano em sintomas, funcionamento pessoal e social, insight e cognição. Métodos: Análise naturalística, longitudinal, no início e no follow-up após um ano, de 15 pacientes seguidos numa consulta especializada de TCA. Os pacientes foram submetidos a avaliação estandardizada com o Positive and Negative Syndrome Scale (PANSS) (Escala Positiva e Negativa do Síndroma), Personal and Social Performance Scale (PSP) (Escala de Desempenho Pessoal e Social), Berrios-Markova Scale to Assess Unawareness in Mental Disorder (SUMD) (Escala de Avaliação da Falta de Consciência no Distúrbio Mental), Trails A e B, Digit Span, e o Controlled Oral Word Association Test (COWA) (Teste de Associação Verbal Controlada). Resultados: No follow-up houve melhorias significativas no funcionamento pessoal e social (PSP inicial total: média=46,9; follow-up: média=59,3), e nomeadamente nas atividades socialmente úteis incluindo trabalho e estudos (p=0,012) e relações pessoais e sociais (p=0,033). Três pacientes (20%) pontuaram =>69 no PSP, um bom nível de funcionamento. Porém, não verificámos melhorias significativas nos sintomas (PANSS=56,8), insight subjetivo ou objetivo (Berrios-Markova=10,0 e SUMD=11,0), ou desempenho cognitivo. Conclusões: No follow-up após um ano, os pacientes em TCA revelaram melhorias significativas no funcionamento pessoal e social, especificamente nas atividades socialmente úteis incluindo trabalho e estudos e nas relações pessoais e sociais, mas não registaram melhorias nos sintomas, insight e funcionamento cognitivo.

Palmitate de palipéridone à doses flexibles chez des patients non-aigus atteints de schizophrénie après échec d’un autre traitement par antipsychotiques injectables à action prolongée

2013 ◽  
Vol 28 (S2) ◽  
pp. 107-108
Author(s):  
P. Cherubin ◽  
L. Hargater ◽  
B. Bergmans ◽  
A. Bjorner ◽  
H. Knegtering ◽  
...  
Keyword(s):  
Scale Score ◽  
Social Performance ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Performance Scale

ObjectifsÉvaluer la tolérance, la sécurité d’emploi et la réponse à un traitement par palmitate de palipéridone (PP) à doses flexibles chez des patients non aigus atteints de schizophrénie, après échec d’un traitement par un autre antipsychotique injectable à action prolongée : décanoate d’halopéridol (Déc-Hal), décanoate de flupentixol (Déc-Fpt), décanoate de fluphénazine (Déc-Flu), zuclopenthixol (Zuc) ou rispéridone à libération prolongée (RIS-LP).MéthodesÉtude internationale, prospective, ouverte, de six mois, chez des patients atteints de schizophrénie, non aigus mais insuffisamment contrôlés par d’autres antipsychotiques injectables à action prolongée.Critères d’évaluationTaux de réponse (amélioration ≥ 20 % du score total à la PANSS [Positive and Negative Syndrome Scale]), score à la PSP (Personal and Social Performance scale), événements indésirables (EIs).RésultatsLes analyses ont été réalisées sur la population en intention de traiter de façon stratifiée pour chaque traitement : 53 patients Déc-Hal, 35 Déc-Fpt, 44 Déc-Flu, 42 Zuc, 56 RIS-LP. Les scores totaux moyens à la PANSS initiale variaient de 67,7 ± 20,3 [RIS-LP] à 75,7 ± 13,2 [Déc-Hal]. Entre 71,4 % [RIS-LP] et 85,7 % [Déc-Fpt] des patients ont terminé l’étude. À la fin de l’étude, 53,7 % [Zuc], 54,7 % [Déc-Hal], 59,1 % [Déc-Flu], 61,1 % [RIS-LP] et 61,8 % [Déc- Fpt] des patients ont vu leur score total à la PANSS diminuer d’au moins 20 %. Les scores moyens de PSP de base étaient de 48,7 [Déc-Hal], 59,6 [Déc-Fpt], 53,5 [Déc-Flu], 52,9 [Zuc] et 60,1 [RIS-LP], et le changement en fin d’étude était respectivement de : 5,2 ; 6,1 ; 6,0 ; 6,4 ; et 5,2 (p ≤ 0,0163 pour tous les traitements). Les EIs rapportés au moins une fois dans tous les sous-groupes : douleur au site d’injection, insomnie, trouble psychotique.ConclusionsLe PP à doses flexibles a été bien toléré et a permis une réponse thérapeutique cliniquement significative chez des patients non aigus atteints de schizophrénie, après échec d’un traitement par d’autres antipsychotiques injectables à action prolongée.

scholarly journals Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Eleni Jelastopulu ◽  
Evangelia Giourou ◽  
Giorgos Merekoulias ◽  
Angeliki Mestousi ◽  
Eleftherios Moratis ◽  
...  
Keyword(s):  
Social Performance ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Performance Scale

scholarly journals СТРАТЕГІЯ ТА ПРИНЦИПИ ТЕРАПІЇ ПАЦІЄНТІВ ІЗ ШИЗОФРЕНІЄЮ І КОМОРБІДНИМИ СЕРЦЕВО-СУДИННИМИ ЗАХВОРЮВАННЯМИ

2019 ◽  
pp. 141-144
Author(s):  
Ye. V. Opryа
Keyword(s):  
Mental Disorder ◽  
Short Form ◽  
Social Performance ◽  
Syndrome Scale ◽  
Sf 36 ◽  
Negative Syndrome ◽  
Performance Scale

Коморбідність психічних розладів із соматичною патологією являє собою одну з провідних та надскладних проблем сучасної психіатричної практики, зокрема в питаннях терапії. Шизофренія є одним із найрозповсюдженіших психічних розладів, що характеризується високою частотою поєднання з соматичною патологією, наявність якої відмічають майже у кожного другого хворого на шизофренію. Мета дослідження – на основі комплексного аналізу клініко-психопатологічних особливостей шизофренії, що поєднана із серцево-судинними захворюваннями, розробити стратегію та принципи її терапії. Матеріали і методи. В якості методів дослідження використовували: клініко-психопатологічний метод, який доповнювали застосуванням клінічної рейтингової шкали позитивної та негативної симптоматик (Positive and Negative Syndrome Scale – PANSS) для оцінки психопатологічних проявів; а також психодіагностичний метод із застосуванням модифікованого варіанта методики Дембо–Рубінштейна для визначення особливостей самооцінки загального стану здоров’я та окремо психічного й фізичного здоров’я; адаптованого варіанта методики SUMD (The Scale to Assess Unawareness of Mental Disorder) для оцінки рівня “інсайту” психічної хвороби; та короткого опитувальника сприйняття хвороби (КОCХ, BIPQ) в адаптації В. М. Ялтонського; шкали особистісного та соціального функціонування (Personal and Social Performance Scale (PSP)) та короткої форми опитувальника про стан здоров’я (The 36-Item Short Form Survey (SF-36) для оцінки якості життя обстежених хворих. Результати досліджень та їх обговорення. У дослідженні обстежено 100 хворих на шизофренію (F20), з яких 50 осіб із наявністю хронічної серцево-судинної патології склали основну групу дослідження, 50 пацієнтів без хронічного соматичного обтяження контрольну. До основної групи залучали пацієнтів із шизофренією і серцево-судинними захворюваннями (ССЗ) тривалістю не менше 3-х років, які на момент дослідження були компенсовані. Пацієнти з постінсультними та постінфарктними станами в дослідження не брали. В структурі серцево-судинної патології хворих основної групи переважали: ішемічна хвороба серця – 64 % та гіпертонічна хвороба – 52 %, також були представлені порушення серцевого ритму – 14 %, кардіоміопатії – 6 %, вади серця (4 %) та варикозне розширення судин (4 %). У більшості випадків спостерігали коморбідність декількох серцево-судинних захворювань одночасно. Висновки. Виділено та описано провідні стратегічні завдання та тактику терапії хворих, що включали: купірування антипсихотичної симптоматики з урахуванням специфіки соматичного стану; опанування навичок контролю соматичного симптому та стресу, а також підвищення соціальної компетентності та соціально-особистісного функціонування пацієнтів. Урахування соматичного стану осіб із коморбідними серцево-судинними захворюваннями дозволяє підвищити рівень їх соціальної компетентності.

Short- and long-term studies of sediment dynamics in a small humid mountain Mediterranean basin with badlands

Geomorphology ◽  
2013 ◽  
Vol 196 ◽  
pp. 242-251 ◽  
Author(s):  
F. Gallart ◽  
N. Pérez-Gallego ◽  
J. Latron ◽  
G. Catari ◽  
N. Martínez-Carreras ◽  
...  
Keyword(s):  
Mediterranean Basin ◽  
Sediment Dynamics ◽  
Short And Long Term ◽  
Long Term Studies

scholarly journals Effect of Pericampylus glaucus on plasma glucose concentration and lipid profile in streptozotocin-induced diabetic rats

2016 ◽  
Vol 11 (1) ◽  
pp. 200 ◽  
Author(s):  
Muhammad Kifayatullah ◽  
Pinaki Sengupta
Keyword(s):  
Lipid Profile ◽  
Plasma Glucose ◽  
Glucose Concentration ◽  
Ethanolic Extract ◽  
Diabetic Rats ◽  
Plasma Glucose Concentration ◽  
Short And Long Term ◽  
Different Doses ◽  
Long Term Studies

<p class="Abstract">The purpose of this study was to evaluate the effects of <em>Pericampylus glaucus</em> extract on plasma glucose concentration and lipid profile in normal and streptozotocin-induced diabetic rats. The ethanolic extract were administered orally at three different doses (400, 600 and 800 mg/kg) and glibenclamide (20 mg/kg p.o.) for 21 days after 72 hours of streptozotocin injection. During the short- and long-term studies, the extract was found to possess significant (p&lt;0.01, p&lt;0.001) anti-diabetic activity in normal and diabetic rats compared with untreated normal and untreated diabetic group. It also caused reduction in the level of total cholesterol, triglyceride, and LDL etc. and improvement in the HDL level compared with untreated diabetic rats. Reduction in the fasting blood sugar, cholesterol, triglyceride, urea, LDL, creatinine levels and improvement in the HDL by<em> P. glaucus</em> indicates that plant has anti-diabetic activity along with anti hyperlipidemic efficacy and provides a scientific rationale for the use.</p><p> </p>

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial

CNS Spectrums ◽  
2013 ◽  
Vol 18 (1) ◽  
pp. 43-54 ◽  
Author(s):  
Andrew J. Cutler ◽  
Amir H. Kalali ◽  
Greg W. Mattingly ◽  
Jelena Kunovac ◽  
Xiangyi Meng
Keyword(s):  
Serum Glucose ◽  
Favorable Effect ◽  
Controlled Clinical Trial ◽  
Open Label ◽  
Once Daily ◽  
Syndrome Scale ◽  
Open Label Extension ◽  
Negative Syndrome ◽  
Extension Trial

Introduction/ObjectiveLong-term use of the atypical antipsychotic iloperidone has not been investigated at doses above 16 mg/d. This article describes safety and tolerability results from the 25-week open-label extension of a 4-week placebo- and ziprasidone-controlled clinical trial of iloperidone.MethodsPatients received a dose of 24 mg/d (given as 12 mg twice daily; mean dose = 21.6 mg) that could be reduced to 12 mg/d (given once daily at bedtime) any time after day 35 at the investigator's discretion.ResultsA total of 72/173 patients (41.6%) completed the open-label extension. Treatment-emergent adverse events (TEAEs), most mild to moderate in severity, included headache (13.9%), weight increase (9.2%), dizziness (6.9%), nausea (6.4%), sedation (6.4%), and insomnia (5.2%). The only notable dose-related TEAEs were increased weight and headache. Levels of serum glucose, lipids, and prolactin were essentially unchanged or decreased during treatment. In general, akathisia and extrapyramidal symptoms (EPS) improved or were unchanged during treatment. There was no signal of worsening of efficacy based on changes from baseline in the Positive and Negative Syndrome Scale-Total.Discussion/ConclusionThis study further supports the long-term safety and tolerability of iloperidone for the treatment of schizophrenia, including iloperidone's favorable effect on metabolic laboratory parameters and low propensity to cause akathisia or EPS.

scholarly journals The Current Dietary Risk Assessment of Chemicals in Food Underestimates the Actual Risk

2019 ◽  
Vol 73 (10) ◽  
pp. 832-834
Author(s):  
Jürg A. Zarn ◽  
H. Christoph Geiser
Keyword(s):  
Daily Intake ◽  
Added Value ◽  
Toxic Substances ◽  
Dietary Risk ◽  
Short And Long Term ◽  
Exposure Levels ◽  
Design Factors ◽  
Dietary Risk Assessment ◽  
Long Term Studies

Dietary risk assessments (DRA) help determine safe exposure levels of toxic substances in food. Of these, Acceptable Daily Intake (ADI), derived from No Observed Adverse Effect Levels (NOAEL) of long-term toxicity studies, is compared to exposure estimates using lifetime-averaged food intakes. These estimates ignore intermittent high exposures exceeding the ADI; toxic effects of such exposures are considered irrelevant, on the assumption that toxic potency increases with exposure duration, which would be reflected by decreasing NOAELs. However, our statistical analysis of thousands of animal toxicology studies shows that NOAELs after short- and long-term exposure are similar if study design factors are considered. Thus, the short- and long-term potency effects of chemicals are similar. Hence, a short-term toxic effect is generally ignored in current DRA. It accounts for lifetime-averaged but not intermittent high food intakes and, therefore, must be revised. Additionally, there is no added value of long-term studies for ADI derivation.

scholarly journals Does corporate social performance lead to better financial performance? Evidence from Turkey

Green Finance ◽  
2021 ◽  
Vol 3 (4) ◽  
pp. 463-481
Author(s):  
Hakan KURT ◽  
◽  
Xuhui Peng ◽  
Keyword(s):  
Financial Performance ◽  
Corporate Strategy ◽  
Corporate Social Performance ◽  
Social Performance ◽  
Positive Role ◽  
Stakeholder Perspective ◽  
Short And Long Term ◽  
Corporate Social ◽  
The Impact

<abstract> <p>In the past two decades, research on the relationship between corporate social performance (CSP) and corporate financial performance (CFP) has seen considerable growth; however, evidence from Turkey remains scarce, and the results are not uniform. To address this lack, this study investigates the impact of CSP on CFP from the perspective of stakeholder theory. Following the investigation of 47 publicly listed companies from the BIST Corporate Governance Index (XKURY) in the period 2014–2018. The results demonstrate that CSP positively affects CFP in both the short and long term. This study addresses the lack of Turkish experience, and the results indicate that CSP is an intangible resource in corporate strategy that can improve the competitive power of Turkish enterprises. Furthermore, the study emphasizes the positive role of CSP in short-term and long-term CFP in the Turkish context from the stakeholder perspective. The results have implications for Turkish policymakers regarding the rational use of corporate social responsibility (CSR) to promote economic development and insights for Turkish enterprises in terms of gaining stakeholders' trust and improving investors' valuation through the strategic use of CSR to achieve long-term, sustainable development of enterprise competitiveness and finance.</p> </abstract>

scholarly journals Tofacitinib: efficiency and safety in long-term use

2019 ◽  
pp. 64-71
Author(s):  
N. V. Chichasova
Keyword(s):  
Rheumatoid Arthritis ◽  
Functional Ability ◽  
Standard Therapy ◽  
Effective Drug ◽  
Highly Effective ◽  
Short And Long Term ◽  
Long Term Studies

The article presents the data of international and domestic controlled studies, in which the effectiveness of topacitinib in the period of 6-24 months is evaluated in respect of clinical and laboratory manifestations of RA activity, progression of destructive arthritis and functional ability of rheumatoid arthritis patients. Also the data of efficiency and safety of tofacitinib in long terms - up to 96 months - are given. According to the results of short- and long-term studies, tofacitinib is a highly effective drug for the treatment of patients with active RA who have not responded to standard therapy with UCVD and GIBP. Tofacitinib is also highly effective in monotherapy. Tolerability of the drug is comparable with other variants of RA treatment.

Sign in / Sign up

Export Citation Format

Share Document